相关实验视频

Updated: Jul 8, 2025

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

吞气球治疗与西马格卢提德口服配方组合的效果:一个随机双盲单中心研究

Winni Mathur¹, Susmit Kosta¹, Manoj Reddy¹

¹Mohak Bariatrics and Robotics Center, Sri Aurobindo University, Indore-Ujjain Highway, Indore, Madhya Pradesh, 453555, India.

Obesity surgery

|December 13, 2023

概括

吞气球手术与西马格卢提德的结合显著提高体重减轻和改善与肥胖相关的条件,与单独的手术相比. 这种新的治疗方法为管理肥胖提供了一个有前途的非手术选择.

科学领域:

减肥干预措施减肥干预措施
药物质量管理重量管理
肥胖和代谢疾病研究研究.

背景情况:

肥胖是一个关键的公共卫生挑战,需要创新的治疗策略.
越来越需要有效的非手术和药物干预措施来控制体重.

研究的目的:

评估一种新的吞气球手术与西马格卢提德结合用于减肥的疗效.
为了比较吞气球治疗的结果,有和没有西马格卢提德的管理.

主要方法:

这是一项随机,双盲,单中心的研究,涉及115名参与者.
参与者被分配到吞气球疗法 (I组) 或没有 (II组) 口服黄胺.
在四个月的时间里,塞马格卢提德剂量升级;数据被统计分析.

主要成果:

在所有时间点上,I组 (用西马格卢) 的总体重减轻率 (%TWL) 较高 (17.6%在4个月),相比于II组 (13.7%在4个月).
在第一组的2型糖尿病 (T2DM),高血压 (HTN) 和阻塞性睡眠呼吸暂停 (OSA) 的解决率中观察到显著的改善.
在手术后的两组中,生活质量 (QoL) 显著改善,没有报告重大晚期并发症.

结论:

吞气球疗法与口服赛马格卢提德相结合,有效促进显著的减肥.
这种综合方法显示了改善与肥胖相关的并发症和增强患者QOL的潜力.
这些发现支持这种联合治疗的发展,作为肥胖管理的可行的非手术选择.

关键词:

非外科手术的方法.肥胖问题肥胖问题塞马格卢提德 (semaglutide) 是一种类型的吞下一个气球.减肥的方法减肥的方法减肥的方法

更多相关视频

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Published on: November 9, 2016

A Murine Model of Vertical Sleeve Gastrectomy

A Murine Model of Vertical Sleeve Gastrectomy

Published on: December 18, 2017

相关概念视频

Upper GI Series: Barium Swallow

Upper GI Series: Barium Swallow

The Barium Swallow Study, or a Barium Esophagogram, is a diagnostic imaging method used to visualize the upper gastrointestinal (GI) tract, including the esophagus, stomach, and small intestine. It employs barium sulfate, a radiopaque contrast material, to provide clear images of the upper digestive system, helping to identify abnormalities, diseases, or structural issues.
Purpose and Procedure
Patients undergoing this procedure ingest a liquid containing barium sulfate with a chalky...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...